公开(公告)号：US20160145333A1

公开(公告)日：2016-05-26

申请号：US14899551

申请日：2014-06-25

Applicant: AMGEN INC.

Inventor： Peter COWARD ,  Steven A. MOORE, Jr. ,  Shi-Yuan MENG ,  Mei-Mei TSAI ,  Chadwick Terence KING ,  Aaron Avraham NAZARIAN

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.

Abstract translation: 本公开涉及CB1受体抗原结合蛋白，例如 抗体和使用CB1受体抗体的方法。 CB1受体抗体可以包含对CB1受体的拮抗性抗体，并且可以用于治疗各种健康状况。 健康状况可以包括肥胖症或糖尿病或从CB1受体的拮抗作用中受益的任何疾病。

公开(公告)号：US20210340262A1

公开(公告)日：2021-11-04

申请号：US17205144

申请日：2021-03-18

Applicant: AMGEN INC.

Inventor： Huiquan HAN ,  Xiaolan ZHOU ,  Qing CHEN ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61P21/00 ,  C07K16/46 ,  C07K16/42

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

公开(公告)号：US20240327526A1

公开(公告)日：2024-10-03

申请号：US18381745

申请日：2023-10-19

Applicant: AMGEN INC.

Inventor： Huiquan HAN ,  Xiaolan ZHOU ,  Qing CHEN ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61K39/00 ,  A61P21/00 ,  C07K16/42 ,  C07K16/46

CPC classification number: C07K16/2863 ,  A61P21/00 ,  C07K16/42 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

公开(公告)号：US20150274829A1

公开(公告)日：2015-10-01

申请号：US14552289

申请日：2014-11-24

Applicant: AMGEN INC.

Inventor： Frank J. CALZONE ,  Rajendra V. DESHPANDE ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

Abstract translation: 本发明提供与抗IGF-1R抗体有关或衍生自抗IGF-1R抗体的组合物和方法。 在具体实施方案中，本发明提供了结合人IGF-1R，IGF-1R结合片段和此类抗体的衍生物的完整的人，人源化或嵌合抗IGF-1R抗体，以及包含此类片段的IGF-1R结合多肽。 其他实施方案提供编码此类抗体，抗体片段和衍生物和多肽的核酸，包含此类多核苷酸的细胞，制备此类抗体的方法，抗体片段和衍生物和多肽，以及使用此类抗体，抗体片段和衍生物和多肽的方法，包括方法 治疗或诊断具有IGF-1R相关疾病或病症的受试者。

公开(公告)号：US20130236457A1

公开(公告)日：2013-09-12

申请号：US13891781

申请日：2013-05-10

Applicant: AMGEN INC.

Inventor： Frank J. CALZONE ,  Rajendra V. DESHPANDE ,  Mei-Mei TSAI

IPC: A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.